Irinotecan and mismatch repair deficiency.
Power
D G
DG
Department of Medicine, Gastrointestinal Oncology Division, Memorial Sloan Kettering Cancer Center, NY, USA. Electronic address: drdgpower@gmail.com.
Feilchenfeldt
J
J
Department of Oncology, Zurich University Hospital, Zurich, Switzerland.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D054316:Biomarkers, Pharmacological / Q000032:analysis; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002277:Carcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D053843:DNA Mismatch Repair / Q000502:physiology; D049914:DNA Repair-Deficiency Disorders / Q000150:complications*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006801:Humans; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000175:diagnosis / Q000556:secondary / Q000601:surgery; D011184:Postoperative Period; D011379:Prognosis
D054316:Biomarkers, Pharmacological; D000077146:Irinotecan; D002166:Camptothecin